Home Journal of Geriatric Cardiology Article
PDF (5.4 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Guideline and Consensu

Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes

Cardiovascular Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare, Li-Nong JI(), Yun-Dai CHEN()

Abstract

The prevalence of patients with coronary heart disease (CHD) and diabetes mellitus is notably high, posing significant residual cardiovascular risks even after routine interventions such as antihypertensive, lipid-lowering, and antithrombotic treatments. Recent studies have demonstrated that certain glucose-lowering medications confer cardiovascular benefits for patients with type 2 diabetes. However, a survey indicates that cardiologists may not be fully acquainted with the optimal screening timing, indicators, and diagnostic criteria for type 2 diabetes, and there is insufficient awareness and a low rate of prescription of novel glucose-lowering medications with proven cardiovascular efficacy, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i). In this context, based on domestic and international guidelines or consensus and the latest evidence-based evidence, this consensus aims to standardize the glycemic management for patients with acute coronary syndrome, chronic coronary syndrome, and perioperative management for percutaneous coronary intervention. It highlights the key points of screening and diagnosis of type 2 diabetes, and the comprehensive management of cardiovascular risk in patients with CHD. The consensus elaborates on the principles and algorithms of glycemic management for CHD patients, without involving acute complications of diabetes, clarifies the clinical practice of glucose-lowering medications with cardiovascular benefits, and promotes the standardized use of these medications in cardiovascular and other related specialty fields. Additionally, it addresses the glucose-lowering treatment to comprehensively reduce cardiovascular risks.

References

[1]
Zeng YH, Liu J, Liu J, et al. [The expanding needs on lipid-lowering treatment in patients with acute coronary syndrome by applying newly issued definition of extreme high-risk by Chinese Society of Cardiology]. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48: 1039-1046. [Article in Chinese].
[2]
Sun Y, Yu J, Hu D; Investigator of CLARIFY. [Status of β-blocker use and heart rate control in Chinese patients with stable coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi 2016; 44: 19-26. [Article in Chinese].
[3]
Xu LJ, Sona Y, Xu JJ, et al. [Impact of Hyperglycemia at Admission on Cardiovascular Events During Hospitalization in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention]. Chinese Circulation Journal 2020; 35: 1187-1191. [Article in Chinese].
[4]
Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017, 5: 941-950.
Crossref
[5]
Zhou LQ, Zhu D, Xu SL, et al. [Current status and influencing factors for physicians in different departments prescribing novel hypoglycemic agent with cardiovascular benefits]. Zhonghua Yi Xue Za Zhi 2023;103: 578-584. [Article in Chinese].
[6]

Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043−4140.

Crossref Google Scholar
[7]
Chinese Diabetes Society. [Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)]. Chinese Journal of Endocrinology and Metabolism 2021; 37: 311-398. [Article in Chinese].
[8]
Wang YF, Wang QR, Deng J, et al. [The 20 actions for weight loss and healthy weight management among Chinese residents:evidence-based expert recommendations and consensus]. Chin Prev Med 2023; 24: 1137-1144. [Article in Chinese].
[9]
Gu DF, Weng JP, Lu XF, et al. [Chinese Guideline on Healthy Lifestyle to Prevent Cardiometabolic Disea]. Chin Circ J 2020; 35: 209-230. [Article in Chinese].
[10]

de Mulder M, Umans VA, Cornel JH, et al. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med 2013; 173: 1896−1904.

Crossref Google Scholar
[11]

Rakipovski G, Rolin B, Nohr J, et al. The GLP-1 Analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-/-) and LDLr(-/-) mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci 2018; 3: 844−857.

Crossref Google Scholar
[12]

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311−322.

Crossref Google Scholar
[13]

Verma S, Bain SC, Honoré JB, et al. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab 2020; 22: 2193−2198.

Crossref Google Scholar
[14]

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834−1844.

Crossref Google Scholar
[15]
Ye XZh, Shao JQ. [Research progress of long-acting glucagon-like peptide-1 receptor agonist semaglutide]. Chinese Journal of Diabetes Mellitus 2022, 14: 1-8. [Article in Chinese].
[16]

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121−130.

Google Scholar
[17]

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117−2128.

Crossref Google Scholar
[18]

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644−657.

Crossref Google Scholar
[19]

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347−357.

Crossref Google Scholar
[20]
American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care 2024, 47: S158-S178.
Crossref
[21]

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279−1289.

Crossref Google Scholar
[22]

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317−1326.

Crossref Google Scholar
[23]

Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232−242.

Crossref Google Scholar
[24]

Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321: 69−79.

Crossref Google Scholar
[25]

Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA 2019; 322: 1155−1166.

Crossref Google Scholar
[26]

Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560−2572.

Crossref Google Scholar
[27]

Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319−328.

Crossref Google Scholar
[28]

Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017; 377: 723−732.

Crossref Google Scholar
[29]

Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 877−886.

Crossref Google Scholar
[30]

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247−2257.

Crossref Google Scholar
[31]

Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228−1239.

Crossref Google Scholar
[32]
Chinese Endocrinologist, Chinese Medical Doctor Association;Expert group of blood glucose management for Chinese inpatients. [Expert consensus on blood glucose management for Chinese inpatients]. Chinese Journal of Endocrinology and Metabolism 2017; 33: 1-10. [Article in Chinese].
[33]

Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018; 6: 275−286.

Crossref Google Scholar
[34]

Ahmann A, Rodbard HW, Rosenstock J, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015; 17: 1056−1064.

Crossref Google Scholar
[35]
Ji LN. [Recommendations for Chinese Evidence and Expert Guidance on Glucagon-like Peptide 1 Receptor Agonist Weekly Formulations]. Chinese Journal of Diabetes 2022; 30: 405-411. [Article in Chinese].
[36]

Duggan EW, Carlson K, Umpierrez GE. Perioperative hyperglycemia management: an update. Anesthesiolo gy 2017; 126: 547−560.

Crossref Google Scholar
[37]
Expert Group for Updating Chinese Expert Consensus on Metformin in Clinical Practice. [Chinese expert consensus on metformin in clinical practice: 2023 update]. Chinese Journal of Internal Medicine 2023; 62: 619-630. [Article in Chinese].
[38]
Chinese Diabetes Society, National Office for Primary Diabetes Care. [National guidelines for the prevention and control of diabetes in primary care (2022)]. Chinese Journal of Internal Medicine 2022, 61: 249-262. [Article in Chinese].
[39]

Honigberg MC, Chang LS, McGuire DK, et al. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiol 2020; 5: 1182−1190.

Crossref Google Scholar
[40]
Expert Group on Recommendations for primary treatment with glucagon-like peptide-1 receptor agonists for type 2 diabetes, [Recommendations for primary treatment with glucagon-like peptide-1 receptor agonists for type 2 diabetes]. Chinese Journal of Practical Internal Medicine 2023; 43: 32-38. [Article in Chinese].
[41]

Liew A, Lydia A, Matawaran BJ, et al. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement. Nephrology (Carlton) 2023; 28: 415−424.

Crossref Google Scholar
[42]

Committee on the Proper Use of SGLT2 Inhibitors. Recommendations on the proper use of SGLT2 inhibitors. J Diabetes Investig 2020; 11: 257−261.

Crossref Google Scholar
[43]

Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2020; 22: 1857−1868.

Crossref Google Scholar
[44]

Singh AKSingh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol 2022; 14: 329−342.

Crossref Google Scholar
[45]

Riley DR, Essa H, Austin P, et al. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab 2023; 25: 2897−2909.

Crossref Google Scholar
[46]
Joint Committee on the Chinese Guidelines for Lipid Management. [Chinese guidelines for lipid management (2023)]. Chinese Circulation Journal 2023, 38: 237-271. [Article in Chinese].
[47]

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389: 2221−2232.

Crossref Google Scholar
Journal of Geriatric Cardiology
Volume 21 Issue 7,
July 2024
Pages 689-702
DOI: 10.26599/1671-5411.2024.07.007
Cite this article:
Cardiovascular Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare, JI L-N, CHEN Y-D. Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes. Journal of Geriatric Cardiology, 2024, 21(7): 689-702. https://doi.org/10.26599/1671-5411.2024.07.007
Metrics & Citations  
Article History
Copyright
Return